Signaling cascades involved in neuroprotection by subpicomolar pituitary adenylate cyclase-activating polypeptide 38

被引:43
|
作者
David, C [1 ]
Kikuta, T [1 ]
Somogyvari-Vigh, A [1 ]
Arimura, A [1 ]
机构
[1] Tulane Univ, Sch Med, US Japan Biomed Res Labs, Dept Med, New Orleans, LA 70112 USA
关键词
pituitary adenylate cyclase-activating polypeptide (PACAP); subpicomole; signaling; activity-dependent neuroprotective protein (ADNP); neuroprotection;
D O I
10.1385/JMN:27:01:91
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In neuronal/glial cocultures, pituitary adenylate cyclase-activating polypeptide 38 (PACAP38) prevented neuronal death induced by gp120, lipopolysaccharide (LPS), or other toxic agents, but the dose response of the neuroprotective effect is bimodal, with a peak at a subpicomolar concentration and another peak at a subnanomolar to nanomolar concentration. Although the signaling cascade involved in neuroprotection by nanomolar concentration of the peptide has been shown to be mediated by activation of cAMP-dependent protein kinase and subsequent activation of mitogen-activated protein kinase (MAPK), the mechanism for neuroprotection. by a subpicomolar level of PACAP38 remains elusive. In the present study, the signaling involved in neuroprotection by subpicomolar PACAP38 was studied in rat neuronal/glial cocultures. Addition of PACAP38 stimulated expression and activation of extracellular signal-related kinase-type MAPK with a peak response at 10(-13) M; greater concentrations of the peptide induced lesser response. cAMP production also increased at subpicomolar levels of PACAP38, but the level remained unchanged at a level four to five times higher than the base level at concentrations below 10(-11) M. cAMP then started increasing again dose-dependently in a range > 10(-11) MPACAP38. Lipopolysaccharide (LPS)-induced neuronal death, indicated by increased release of neuron-specific enolase, was suppressed by PACAP38 in a bimodal fashion. Neuroprotection by 10(-12) M PACAP38 was completely abolished by a MAPK kinase-1 inhibitor, PD98059, and also partially suppressed by Rp-cAMP, a cAMP-dependent protein kinase inhibitor. Moreover, neuroprotection by a nanomolar level of PACAP38 was completely suppressed by Rp-cAMP but not affected by PD98059. We conclude that neuroprotection by subpicomolar PACAP38 is mainly mediated by the signaling pathway involving MAPK activation and partially regulated by cAMP-dependent protein kinase activation. Furthermore, PACAP38 stimulated expression of activity-dependent neuroprotective protein (ADNP), with a peak at 10(-13) M. Greater doses of the peptide induced lesser response. However, 10(-13) M PACAP38-stimulated expression of ADNP was not affected by PD98059. This suggests that neuroprotection by subpicomolar PACAP38 might be mediated partially by expression of ADNP, but the major events for neuroprotection by subpicomolar PACAP38 remain to be identified.
引用
收藏
页码:91 / 105
页数:15
相关论文
共 50 条
  • [21] INVOLVEMENT OF THE PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE IN EXCESSIVE DRINKING
    Minnig, M. A.
    Sabino, V.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 43 : 154A - 154A
  • [22] Role of Pituitary Adenylate Cyclase-Activating Polypeptide in Nociception and Migraine
    Tajti, Janos
    Tuka, Bernadett
    Botz, Balint
    Helyes, Zsuzsanna
    Vecsei, Laszlo
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2015, 14 (04) : 540 - 553
  • [23] Pituitary adenylate cyclase-activating polypeptide (PACAP) in the rat ovary
    Kotani, E
    Usuki, S
    Kondo, K
    Kubo, T
    CONTROL MECHANISMS OF STRESS AND EMOTION: NEUROENDOCRINE-BASED STUDIES, 1999, 1185 : 269 - 271
  • [24] Effect of Pituitary Adenylate Cyclase-Activating Polypeptide in Islet Transplantation
    Sakuma, Y.
    Ricordi, C.
    Miki, A.
    Yamamoto, T.
    Mita, A.
    Barker, S.
    Damaris, R. M.
    Pileggi, A.
    Yasuda, Y.
    Yada, T.
    Ichii, H.
    TRANSPLANTATION PROCEEDINGS, 2009, 41 (01) : 343 - 345
  • [25] Pituitary adenylate cyclase-activating polypeptide, effects in the human nose
    Kinhult, J
    Adner, M
    Uddman, R
    Cardell, LO
    CLINICAL AND EXPERIMENTAL ALLERGY, 2003, 33 (07): : 942 - 949
  • [26] Pituitary adenylate cyclase-activating polypeptide (PACAP) and islet function
    Ahren, Bo
    REGULATORY PEPTIDES, 2010, 164 (01) : 23 - 23
  • [27] Pituitary adenylate cyclase-activating polypeptide induces hyperthermia in the rat
    Pataki, I
    Adamik, A
    Jászberényi, M
    Mácsai, M
    Telegdy, G
    NEUROPHARMACOLOGY, 2000, 39 (07) : 1303 - 1308
  • [28] PURIFICATION AND CHARACTERIZATION OF THE RECEPTOR FOR PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE
    OHTAKI, T
    MASUDA, Y
    ISHIBASHI, Y
    KITADA, C
    ARIMURA, A
    FUJINO, M
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1993, 268 (35) : 26650 - 26657
  • [29] Cell Penetration Properties of Pituitary Adenylate Cyclase-Activating Polypeptide
    Ngoc-Duc Doan
    Thi Tuyet Mai Nguyen
    Letourneau, Myriam
    Chatenet, David
    Fournier, Alain
    BIOPOLYMERS, 2011, 96 (04) : 471 - 471
  • [30] Pituitary adenylate cyclase-activating polypeptide and its receptors in amphibians
    Yon, L
    Alexandre, D
    Montéro, M
    Chartrel, N
    Jeandel, L
    Vallarino, M
    Conlon, JM
    Kikuyama, S
    Fournier, A
    Gracia-Navarro, F
    Roubos, E
    Chow, B
    Arimura, A
    Anouar, Y
    Vaudry, H
    MICROSCOPY RESEARCH AND TECHNIQUE, 2001, 54 (03) : 137 - 157